文献速递青光眼

奥米替尼异丙酯降低眼压的安全性与有效性:系统评价与Meta分析

Safety and Efficacy of Omidenepag Isopropyl for Elevated Intraocular Pressure: A Systematic Review and Meta-Analysis.
PubMed 文献 · Am J Ophthalmol · 2025-07-24

该系统评价与Meta分析纳入17项研究共3294只眼,比较奥米替尼异丙酯(OMDI)与前列腺素F(FP)受体激动剂。OMDI与FP激动剂降眼压无显著差异(WMD=0.28 mmHg,95%CI -0.09至0.65,P=.144),OMDI相对基线显著降低眼压(WMD=-3.78 mmHg,95%CI -4.74至-2.82,P<.001)。总体眼部不良事件在OMDI组可能更高(RR=1.16,95%CI 0.94至1.43,P=.170),但结膜充血和角膜改变在OMDI组更高,而睫毛和眼睑/眶周副作用在OMDI组更少。

要点

  • OMDI与FP激动剂降眼压无显著差异(WMD=0.28 mmHg,95%CI -0.09至0.65,P=.144)。
  • OMDI相对基线显著降低眼压(WMD=-3.78 mmHg,95%CI -4.74至-2.82,P<.001)。
  • OMDI组结膜充血(14.0% vs 6.8%)和角膜改变(6.7% vs 3.3%)更高,睫毛(0.0% vs 3.0%)和眼睑/眶周副作用(0.0% vs 2.8%)更少。

核心结论

  • OMDI 0.002%为眼压管理提供了FP激动剂的替代选择,尤其当FP激动剂可能无效或不适用时。
  • OMDI疗效与FP激动剂相当,但临床医生必须考虑OMDI不良事件风险增加。
  • 短期随访限制了对长期疗效和罕见不良事件的评估;然而,无睫毛相关改变和前列腺素相关眶周病变提供了相对于FP激动剂的美容优势。
  • 进一步研究可识别可能从OMDI治疗中获益的患者亚组。

研究设计与样本

  • 系统评价与Meta分析,检索MEDLINE、EMBASE和CENTRAL从建库至2024年11月。
  • 共筛选358项研究,纳入17项研究(n=3294只眼),包括5项随机对照试验、7项回顾性队列研究和5项前瞻性队列研究。
  • 眼部不良事件Meta分析采用固定效应模型合并风险比(RR),眼压变化采用随机效应模型合并加权均数差(WMD),结果以95%置信区间(CI)和P值呈现。

主要发现

  • 多数研究为无对照研究,随访时间不一(9.3±8.7个月);平均年龄60.8±11.7岁,男性占44.73%(n=1318)。
  • 4项研究显示OMDI与FP激动剂降眼压无显著差异(WMD=0.28 mmHg,95%CI -0.09至0.65,P=.144)。
  • 17项研究报告OMDI相对基线显著降低眼压(WMD=-3.78 mmHg,95%CI -4.74至-2.82,P<.001)。
  • 总体眼部不良事件在OMDI组可能高于FP受体激动剂组(RR=1.16,95%CI 0.94至1.43,P=.170),排除1项明显 favoring OMDI的研究后变得显著(RR=1.46,95%CI 1.17至1.83,P<.001)。
  • OMDI组结膜充血(14.0% vs 6.8%)和角膜改变(6.7% vs 3.3%)发生率更高(P<.05);睫毛(0.0% vs 3.0%,P=.003)和眼睑/眶周副作用(0.0% vs 2.8%,P=.013)更少。

关键数值与推荐

  • OMDI与FP激动剂降眼压无显著差异:WMD=0.28 mmHg,95%CI -0.09至0.65,P=.144。
  • OMDI相对基线降眼压:WMD=-3.78 mmHg,95%CI -4.74至-2.82,P<.001。
  • 总体眼部不良事件:RR=1.16,95%CI 0.94至1.43,P=.170。
  • 排除1项研究后总体眼部不良事件:RR=1.46,95%CI 1.17至1.83,P<.001。
  • 结膜充血14.0% vs 6.8%、角膜改变6.7% vs 3.3%(OMDI组更高,P<.05);睫毛0.0% vs 3.0%(P=.003)、眼睑/眶周副作用0.0% vs 2.8%(P=.013)(OMDI组更少)。

临床怎么用

  • 作者认为OMDI 0.002%为眼压管理提供了FP激动剂的替代选择,尤其当FP激动剂可能无效或不适用时。
  • 作者指出OMDI疗效与FP激动剂相当,但临床医生必须考虑OMDI不良事件风险增加。
  • 作者认为无睫毛相关改变和前列腺素相关眶周病变提供了相对于FP激动剂的美容优势。

局限性

  • 多数研究为无对照研究,随访时间不一(9.3±8.7个月)。
  • 短期随访限制了对长期疗效和罕见不良事件的评估。
  • 进一步研究可识别可能从OMDI治疗中获益的患者亚组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We synthesized the literature to assess the safety and efficacy of Omidenpag isopropyl (OMDI) in comparison to prostaglandin F(FP) agonists used in glaucoma management DESIGN: Systematic review and meta-analysis. METHODS: We searched MEDLINE, EMBASE and CENTRAL from inception to November 2024. Meta-analyses were conducted using fixed-effects models for ocular adverse events (AEs), with pooled risk ratios (RRs), and random-effects models for intraocular pressure (IOP) changes, with weighted mean differences (WMDs). Results are presented as 95% confidence intervals (CIs) and P-values. RESULTS: Of the 358 studies screened, 17 studies (n = 3294 eyes) were included, yielding 5 RCTs, 7 retrospective cohort studies and 5 prospective cohort studies. Most studies were uncontrolled with variable follow-ups (9.3 ± 8.7 months). The mean age was60.8 ± 11.7 years, and 44.73% were male (n = 1318). The primary efficacy outcome was the change in IOP from baseline. 4 studies indicated no significant difference in IOP reduction between OMDI and FP agonists (WMD = 0.28 mmHg, 95% CI [-0.09 to 0.65], P = .144). 17 studies reported a significant reduction in IOP from baseline with OMDI (WMD = -3.78 mmHg, 95% CI [-4.74 to -2.82], P < .001). Overall ocular AEs may have been higher in patients treated with OMDI when compared to FP receptor agonists (RR = 1.16, 95% CI [0.94 to1.43], P = .170), which became significant with the exclusion of 1 study with a marked effect favoring OMDI (1.46 (95% CI: [1.17 to 1.83], P < .001). Incidence of conjunctival hyperemia (14.0% vs 6.8%) and corneal changes (6.7% vs 3.3%) were higher in the OMDI group (P < .05). However, there were less eyelash (0.0% vs 3.0%, P = .003) and eyelid/orbital side effects (0.0% vs 2.8%, P = .013) with OMDI. CONCLUSION: OMDI 0.002% offers an alternative to FPs for IOP management especially when FPs may not be effective or suitable. While its efficacy is comparable, clinicians must consider the increased risk of AEs with OMDI. Short follow-up periods constrained the assessment of long-term efficacy and rare AEs; however, the absence of eyelash-related changes and prostaglandin associated periorbitopathy offers a cosmetic advantage over FPs. Further research could identify patient subgroups who may benefit from OMDI treatment.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Sharma S, Singh R, Balas M, et al. Safety and Efficacy of Omidenepag Isopropyl for Elevated Intraocular Pressure: A Systematic Review and Meta-Analysis. Am J Ophthalmol. 2025. PMID: 40714057. doi:10.1016/j.ajo.2025.07.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。